Cao M, et al. - Researchers here performed a meta-analysis of all phase 3 randomized controlled trials (RCTs) of regorafenib to quantify the increased risk of SAEs and FAEs. They gained no evidence for the association between regorafenib and higher risk of SAEs and FAEs. This analysis seemed to have implications when considering the trade-off of regorafenib treatment during clinical decision-making.